Tag: glutaminyl cyclase

Company News: Probiodrug Appoints Kumar Srinivasan as Chief Business Officer

Probiodrug (Halle, Germany) has appointed Dr Kumar Srinivasan, previously Vice President, Global Business Development at Wyeth, to Chief Business Officer. Wyeth was acquired by Pfizer in 2009. Probiodrug has a focus on neurodegenerative diseases, in particular Alzheimer’s disease. In this indication, the company pursues a novel target and pathway and is preparing for the start of clinical development of one of its lead candidates, a small molecule inhibitor of the enzyme glutaminyl cyclase (QC). Kumar Srinivasan, MBA, has a background as research chemist and is an experienced pharma / biotech dealmaker. He will be responsible for Probiodrug’s global business development activities and will be based in Philadelphia, PA. The full press release can be found here.